Análise Do Mercado De Diagnóstico Do Câncer De Rim Na ásia-Pacífico Em 2030

Asia Pacific Kidney Cancer Diagnostics Market

Tamanho do mercado em biliões de dólares

CAGR : 6.90 %

Período de previsão	2024 –2030
Tamanho do mercado (ano base )	US$ MILHÕES Pedido
Tamanho do mercado ( Ano de previsão)	USD 3,240.00
CAGR	6.90 %
Principais participantes do mercado	Manequim1 Manequim2 Manequim3 Manequim4 Manequim5 Pedido de desbloqueio

Mercado de diagnóstico de cancro renal Ásia-Pacífico, por tipo de teste (imagiologia, teste de biomarcador, análise ao sangue, biópsia, teste genético e outros), estádio de cancro (estádio I, estádio II, estádio III e estádio IV), tipo de tumor (renal Carcinoma de células, Carcinoma de células renais de células claras, Carcinoma de células renais de células não claras), Produto (produtos baseados em plataforma, produtos baseados em instrumentos, kits e reagentes e outros consumíveis), tecnologia ( hibridização fluorescente in situ , sequenciação de nova geração, fluorimunoensaio, comparativo Hibridização genómica, imunohistoquímica e outros), aplicação (rastreio, diagnóstico e preditivo, prognóstico e investigação), utilizador final (hospitais, centros de diagnóstico, centros de investigação oncológica, institutos académicos, centros de cirurgia ambulatória e outros), canal de distribuição (directo Concurso, Vendas a Retalho e Outros), Tendências do Sector e Previsão para 2030.

Análise e dimensão do mercado de diagnóstico de cancro renal da Ásia-Pacífico

O cancro renal começa quando as células saudáveis num ou em ambos os rins se alteram e crescem incontrolavelmente, formando uma massa chamada tumor cortical. O tumor pode ser maligno, indolente ou benigno. A malignidade é cancro, o que significa que pode crescer e espalhar-se para outras partes do corpo. Um tumor indolente é também cancro, mas este tipo de tumor raramente se espalha para outras partes do corpo. Um tumor benigno significa que o tumor pode crescer, mas não se espalhar.

A crescente consciencialização sobre o cancro renal na Ásia-Pacífico aumentou a procura do mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento da melhoria dos procedimentos de diagnóstico do cancro do rim também contribui para o aumento da procura de testes de diagnóstico do cancro do rim.

Espera-se que o mercado de diagnóstico de cancro renal da Ásia-Pacífico cresça no ano previsto devido ao aumento dos participantes do mercado e à disponibilidade de serviços avançados. A par disto, os fabricantes estão empenhados em atividades de I&D para lançar novos serviços no mercado. Espera-se que a crescente investigação na área do diagnóstico e desenvolvimento renal impulsione ainda mais o crescimento do mercado. No entanto, espera-se que os danos nos tecidos devido à elevada exposição à radiação dos testes de imagem dificultem o crescimento do mercado de diagnóstico de cancro renal da Ásia-Pacífico no período de previsão.

A Data Bridge Market Research analisa que o mercado de diagnóstico de cancro renal deverá atingir um valor de 3.240,00 milhões de dólares até 2030, com um CAGR de 6,9% no período de previsão. A imagem é responsável pelo maior segmento de tipos de testes do mercado devido à crescente procura de dispositivos inteligentes, e o aumento dos gastos com a saúde acelerou a procura de dispositivos médicos inteligentes.

Métrica de reporte	Detalhes
Período de previsão	2023 a 2030
Ano base	2022
Anos históricos	2021 (personalizável para 2020-2016)
Unidades Quantitativas	Receita em milhões de dólares, volumes em unidades, preços em dólares
Segmentos cobertos	Por tipo de teste (imagiologia, teste de biomarcador, análise ao sangue, biópsia, teste genético e outros), estádio de cancro (estádio I, estádio II, estádio III e estádio IV), tipo de tumor (carcinoma de células renais, carcinoma de células renais de células claras , carcinoma de células renais de células não claras), produto (produtos baseados em plataforma, produtos baseados em instrumentos, kits e reagentes e outros consumíveis), tecnologia (hibridização in situ fluorescente, sequenciação de nova geração, fluorimunoensaio , hibridização genómica comparativa, imunohistoquímica e outros) , Aplicação (rastreio, diagnóstico e preditivo, prognóstico e investigação), utilizador final (hospitais, centros de diagnóstico, centros de investigação oncológica, institutos académicos, centros de cirurgia ambulatória e outros), canal de distribuição (concurso direto, vendas a retalho e outros) .
Países abrangidos	China, Japão, Índia, Austrália, Nova Zelândia, Coreia do Sul, Singapura, Malásia, Tailândia, Indonésia, Filipinas, Vietname, Taiwan e restante Ásia-Pacífico.
Participantes do mercado abrangidos	Siemens Healthcare GmbH, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene NV, GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D e CD Genomics e BD, entre outros

Definição de mercado

O cancro renal, vulgarmente conhecido como cancro do rim, é uma condição na qual as células renais se transformam em tumores malignos (cancerígenos) e se expandem incontrolavelmente. Um dos 10 tipos de cancro mais prevalentes é o cancro do rim. O cancro do rim é fatal e o processo de diagnóstico também apresenta problemas de segurança; não é rentável. Os doentes oncológicos podem ser hospitalizados e receber uma variedade de terapias, como cirurgia, radioterapia e terapia sistémica. Cerca de 40% dos crescimentos renais são pequenas massas localizadas. Localizado refere-se a um tumor que não se espalhou a partir da sua localização original. As massas renais não podem ser detectadas com procedimentos laboratoriais regulares. O diagnóstico de cancro renal inclui procedimentos de biópsia, análises ao sangue e exames de imagem. Terapias avançadas para o cancro renal, como a imunoterapia, radioterapia, etc., são recomendadas. Devido aos métodos de ponta, os procedimentos não cirúrgicos como a crioablação (que congela as células cancerígenas) e a ablação por radiofrequência são por vezes utilizados para tratar tumores renais mais pequenos (células cancerígenas pelo calor).

O cancro do rim pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, são inespecíficos e podem estar associados a outras condições médicas mais generalizadas. Mais de 43.000 homens e 25.000 mulheres são diagnosticados com cancro do rim e da pélvis renal por ano, e 9.000 homens e 5.000 mulheres morrem em consequência desta doença. No entanto, espera-se que os regulamentos e normas rigorosos para a aprovação e comercialização de produtos para o diagnóstico do cancro do rim restrinjam o crescimento do mercado.

Dinâmica do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:

Motoristas

Crescente prevalência de cancro renal

Todas as idades podem ser afetadas por este tipo de cancro. O cancro do rim pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, são inespecíficos e podem estar associados a outras condições médicas mais generalizadas. O cancro do rim geralmente não apresenta sinais ou sintomas nos seus estágios iniciais. Com o tempo, podem ocorrer sinais e sintomas, incluindo sangue na urina, que pode parecer cor-de-rosa, vermelho ou cor de cola, dor nas costas ou nos lados que não desaparece, perda de apetite, perda de peso inexplicável, fadiga e febre. Nos adultos, o cancro do rim é o tipo mais comum de cancro. As crianças pequenas têm maior probabilidade de desenvolver um tipo de cancro renal chamado tumor de Wilms. O cancro do rim (também conhecido como cancro do rim ou adenocarcinoma de células renais) é o 14º cancro mais comum em todo o mundo. É o 9º entre os homens e o 14º entre as mulheres. Em 2020, foram diagnosticados mais de 30 mil novos casos de cancro renal.

Devido a vários factores de risco, como o tabagismo, a obesidade, a pressão arterial elevada (hipertensão) ou antecedentes familiares de cancro do rim, os doentes com cancro do rim estão a aumentar na Ásia-Pacífico e a tornar-se um problema socioeconómico significativo. Assim, o número crescente de doentes com cancro renal aumenta a procura de produtos de diagnóstico de cancro renal que atuem como impulsionadores do mercado de diagnóstico de cancro renal da Ásia-Pacífico.

Aumento dos procedimentos de diagnóstico para o cancro renal

As técnicas utilizadas para diagnosticar o cancro do rim incluem a ecografia, a tomografia computorizada (TC), a ressonância magnética (RM) e, por vezes, a tomografia por emissão de positrões (PET). O tratamento do cancro do rim com taxa de crescimento lenta pode envolver monitorização. A quimioterapia para tumores malignos é ocasionalmente combinada com radioterapia e transplante de células estaminais. O aumento das taxas de cancro tem sido um fator impulsionador para a crescente aprovação de produtos de diagnóstico.

Assim, o aumento das aprovações de produtos de diagnóstico levou a um aumento do número de produtos altamente eficientes no mercado para o tratamento do diagnóstico do cancro do rim. Espera-se que isto atue como um impulsionador para o crescimento do mercado de diagnóstico de cancro renal da Ásia-Pacífico.

Oportunidade

Crescente preferência por exames de saúde preventivos

O check-up preventivo de saúde são ações preventivas realizadas para a deteção inicial do cancro do rim. Além disso, uma preferência crescente por exames de saúde preventivos proporciona uma salvaguarda contra a provável exposição a qualquer doença no futuro.

A sensibilização para promover o rastreio é a componente mais importante da prevenção do cancro do rim. O check-up consiste na identificação do cancro e exames de fatores de risco para limitar a perda numa fase inicial.

O check-up preventivo do cancro do rim é realizado com o auxílio de diversos exames de diagnóstico, que incluem biópsia, imunohistoquímica, rastreio do cancro, ressonância magnética e entre outros.

As pessoas são relativamente mais propensas a doenças cancerígenas renais. Por conseguinte, exigem a realização de check-ups regulares para facilitar aos médicos o desenvolvimento de uma compreensão das doenças e para prestar um melhor tratamento a um doente que sofre de cancro, pela razão pela qual se espera que a crescente preferência por check-ups preventivos de saúde atue como um impulsionador para o crescimento do mercado de diagnóstico de cancro renal da Ásia-Pacífico.

Restrição/Desafio

Regulamentação e normas rigorosas para aprovação e comercialização de produtos para diagnóstico de cancro renal

As rigorosas regulamentações para a comercialização de qualquer produto no mercado estão a revelar-se um grande desafio para os fabricantes de produtos de diagnóstico de cancro na Ásia-Pacífico, que possuem regulamentos e um organismo diferente para os procedimentos regulamentares.

Os fabricantes precisam primeiro de verificar a aprovação da marca CE para a comercialização dos seus produtos no mercado da Ásia-Pacífico. Espera-se que as rigorosas políticas regulamentares atrapalhem o desenvolvimento do mercado de diagnóstico do cancro. A exigência regulamentar para aprovações de comercialização ou certificação CE e aplicação de leis e regulamentos pode levar a grandes mudanças nos negócios ou ao pagamento de penalizações, incluindo a potencial perda de licenças comerciais. Os recursos e custos necessários para cumprir estas leis, regras e regulamentos são elevados.

Os requisitos regulamentares para as aprovações de comercialização, a declaração de conformidade e o tempo necessário para a revisão regulamentar podem variar de produto para produto. A empresa que não consegue a aprovação regulamentar prejudica o negócio porque, sem obter a aprovação ou sem conseguir que a CE marque a aprovação dos produtos, os fabricantes não conseguem lançar os seus produtos no mercado da Ásia-Pacífico e, por esse motivo, as regulamentações rigorosas e espera-se que as normas para a aprovação e comercialização de produtos de diagnóstico do cancro do rim funcionem como uma restrição para o mercado de diagnóstico do cancro do rim da Ásia-Pacífico.

Desenvolvimentos recentes

Em novembro de 2022, a Koninklijke Philips NV anunciou o lançamento na Ásia-Pacífico de uma solução de ecografia portátil compacta de próxima geração na reunião anual da Sociedade Radiológica da América do Norte (RSNA) para levar a qualidade de diagnóstico associada aos sistemas de ecografia premium baseados em carrinho para mais doentes . É portátil e versátil, com boa qualidade de imagem ou desempenho. É compatível com os sistemas de ultrassons Philips Affiniti e transdutor EPIQ. Isto ajudou a empresa a expandir o seu portfólio de produtos.
Em outubro de 2022, a General Electric Company colaborou com vários institutos de investigação como os hospitais da Universidade de Cambridge, Sophia Genetics e, anteriormente, com a Optellum para utilizar dados de imagem em colaboração com a inteligência artificial. Isto ajudará a reduzir o tempo de diagnóstico de vários tipos de cancro e a prestar cuidados personalizados aos pacientes. Isto ajudou a empresa a alargar os seus horizontes no diagnóstico de cancro.
Em julho de 2022, a Canon Medical Systems USA Inc. anunciou a conclusão da aquisição da NXC Imaging, um distribuidor e prestador de serviços de equipamentos de imagiologia médica localizado em Minnesota, EUA. -Pacífico.

Âmbito do mercado de diagnóstico de cancro renal da Ásia-Pacífico

O mercado de diagnóstico do cancro do rim da Ásia-Pacífico está segmentado em oito segmentos notáveis com base no tipo de teste, estádio do cancro, tipo de tumor, produto, aplicação, tecnologia, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

Tipo de teste

TESTE DE IMAGEM
TESTE DE BIOMARCADOR
TESTE DE SANGUE
BIÓPSIA
TESTE GENÉTICO
OUTROS

Com base no tipo de teste, o mercado de diagnóstico de cancro renal da Ásia-Pacífico está segmentado em imagens, testes de biomarcadores, análises ao sangue, biópsia, testes genéticos, entre outros.

Estágio do cancro

ESTÁGIO I
ESTÁGIO II
ESTÁGIO III
ESTÁGIO IV

Com base no estádio do cancro, o mercado de diagnóstico do cancro do rim da Ásia-Pacífico está segmentado no estádio I, estádio II, estádio III e estádio IV.

Tipo de tumor

CARCINOMA DE CÉLULAS RENAIS
CARCINOMA DE CÉLULAS RENAIS DE CÉLULAS CLARAS
CARCINOMA DE CÉLULAS RENAIS DE CÉLULAS NÃO CLARAS

Com base no tipo de tumor, o mercado de diagnóstico de cancro renal da Ásia-Pacífico está segmentado em carcinoma de células renais, carcinoma de células renais de células claras e carcinoma de células renais de células não claras.

Produto

PRODUTOS BASEADOS EM PLATAFORMA
PRODUTOS BASEADOS EM INSTRUMENTOS
KITS E REAGENTES
OUTROS CONSUMÍVEIS

Com base no produto, o mercado de diagnóstico do cancro do rim da Ásia-Pacífico está segmentado em produtos baseados em instrumentos, produtos baseados em plataformas, kits e reagentes e outros consumíveis.

Tecnologia

HIBRIDIZAÇÃO FLUORESCENTE IN SITU
SEQUENCIAÇÃO DE PRÓXIMA GERAÇÃO
FLUORIMUNOASSAO
HIBRIDIZAÇÃO GENÓMICA COMPARATIVA
IMUNO-HISTOQUÍMICA
OUTROS

Com base na tecnologia, o mercado de diagnóstico de cancro renal da Ásia-Pacífico está segmentado em hibridização fluorescente in situ, sequenciação de nova geração, fluorimunoensaio, hibridização genómica comparativa, imunohistoquímica, entre outros.

Aplicação

TRIAGEM
DIAGNÓSTICO E PREDITIVO
PROGNÓSTICO
INVESTIGAÇÃO

Com base na aplicação, o mercado de diagnóstico de cancro renal da Ásia-Pacífico está segmentado em rastreio, diagnóstico e preditivo, prognóstico e investigação.

Utilizador final

HOSPITAIS
CENTROS DE INVESTIGAÇÃO DE CÂNCER
INSTITUTOS ACADÉMICOS
CENTROS DE DIAGNÓSTICO
CENTROS CIRÚRGICOS AMBULATÓRIOS
OUTROS

Com base nos utilizadores finais, o mercado de diagnóstico do cancro do rim da Ásia-Pacífico está segmentado em hospitais, centros de diagnóstico, centros de investigação do cancro, institutos académicos, centros de cirurgia ambulatória, entre outros.

Canal de Distribuição

PROPOSTAS DIRETAS
VENDAS NO VAREJO
OUTROS

Com base no canal de distribuição, o mercado de diagnóstico do cancro do rim da Ásia-Pacífico está segmentado em licitação direta, vendas a retalho e outros.

Análise/perspetivas regionais do mercado de diagnóstico de cancro renal da Ásia-Pacífico

O mercado de diagnóstico de cancro renal da Ásia-Pacífico é analisado e são fornecidas informações sobre o tamanho do mercado com base no país, tipo de teste, fase do cancro, tipo de tumor, produto, aplicação, tecnologia, utilizador final e canal de distribuição.

Os países abrangidos neste relatório de mercado são a China, Japão, Índia, Austrália, Nova Zelândia, Coreia do Sul, Singapura, Malásia, Tailândia, Indonésia, Filipinas, Vietname, Taiwan e o resto da Ásia-Pacífico.

A China domina a região Ásia-Pacífico devido à crescente consciencialização sobre os exames de saúde regulares.

A secção de países do relatório também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas da Ásia-Pacífico e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Análise do panorama competitivo e da quota de mercado de diagnóstico de cancro renal da Ásia-Pacífico

O panorama competitivo do mercado de diagnóstico do cancro do rim fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e amplitude do produto, domínio de aplicação e tipo de produto curva da linha de vida. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de diagnóstico do cancro do rim.

Alguns dos principais players que operam no mercado são a Siemens Healthcare GmbH, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene NV, GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D e CD Genomics, BD, entre outros.

SKU-69723

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES

4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES

5 INDUSTRY INSIGHTS

6 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING PREVALENCE OF KIDNEY CANCER

7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER

7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER

7.2 RESTRAINTS

7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS

7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

7.3 OPPORTUNITIES

7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS

7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE

7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS

7.4 CHALLENGES

7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS

8 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING

8.2.1 COMPUTED TOMOGRAPHY

8.2.2 ULTRASOUND

8.2.3 MAGNETIC RESONANCE IMAGING (MRI)

8.2.4 ANGIOGRAPHY

8.2.5 X-RAY

8.2.6 OTHERS

8.3 BLOOD TEST

8.4 BIOPSY

8.4.1 FINE NEEDLE ASPIRATION

8.4.2 NEEDLE CORE BIOPSY

8.5 BIOMARKER TEST

8.5.1 AQUAPORIN 1 (AQP1)

8.5.2 PERILIPIN (PLIN2)

8.5.3 N-METHYLTRANSFERASE (NMNT)

8.5.4 L-PLASTIN (LCP-1)

8.5.5 NM23A

8.6 GENETIC TEST

8.7 OTHERS

9 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE

9.1 OVERVIEW

9.2 STAGE I

9.3 STAGE II

9.4 STAGE III

9.5 STAGE IV

10 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE

10.1 OVERVIEW

10.2 RENAL CELL CARCINOMA

10.2.1 IMAGING

10.2.2 BLOOD TEST

10.2.3 BIOPSY

10.2.4 BIOMARKER TEST

10.2.5 GENETIC TEST

10.2.6 OTHERS

10.3 CLEAR CELL RENAL CELL CARCINOMA

10.3.1 IMAGING

10.3.2 BLOOD TEST

10.3.3 BIOPSY

10.3.4 BIOMARKER TEST

10.3.5 GENETIC TEST

10.3.6 OTHERS

10.4 NON CLEAR CELL RENAL CELL CARCINOMA

10.4.1 PAPILLARY RENAL CELL CARCINOMA

10.4.1.1 IMAGING

10.4.1.2 BLOOD TEST

10.4.1.3 BIOPSY

10.4.1.4 BIOMARKER TEST

10.4.1.5 GENETIC TEST

10.4.1.6 OTHERS

10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA

10.4.2.1 IMAGING

10.4.2.2 BLOOD TEST

10.4.2.3 BIOPSY

10.4.2.4 BIOMARKER TEST

10.4.2.5 GENETIC TEST

10.4.2.6 OTHERS

11 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT

11.1 OVERVIEW

11.2 INSTRUMENT BASED PRODUCTS

11.2.1 IMAGING

11.2.2 BIOPSY

11.3 PLATFORM BASED PRODUCTS

11.3.1 NEXT GENERATION SEQUENCING

11.3.2 MICROARRAYS

11.3.3 PCR

11.3.4 OTHERS

11.4 KITS AND REAGENTS

11.4.1 RENAL CANCER PANELS

11.4.2 RENAL CANCER ANTIBODIES

11.5 OTHER CONSUMABLES

12 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

12.1 OVERVIEW

12.2 FLUORESCENT IN SITU HYBRIDIZATION

12.3 NEXT GENERATION SEQUENCING

12.4 FLUORIMMUNOASSAY

12.5 COMPARATIVE GENOMIC HYBRIDIZATION

12.6 IMMUNOHISTOCHEMICAL

12.7 OTHERS

13 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 SCREENING

13.2.1 INSTRUMENT BASED PRODUCTS

13.2.2 PLATFORM BASED PRODUCTS

13.2.3 KITS AND REAGENTS

13.2.4 OTHER CONSUMABLES

13.3 DIAGNOSTIC AND PREDICTIVE

13.3.1 INSTRUMENT BASED PRODUCTS

13.3.2 PLATFORM BASED PRODUCTS

13.3.3 KITS AND REAGENTS

13.3.4 OTHER CONSUMABLES

13.4 PROGNOSTIC

13.4.1 INSTRUMENT BASED PRODUCTS

13.4.2 PLATFORM BASED PRODUCTS

13.4.3 KITS AND REAGENTS

13.4.4 OTHER CONSUMABLES

13.5 RESEARCH

13.5.1 INSTRUMENT BASED PRODUCTS

13.5.2 PLATFORM BASED PRODUCTS

13.5.3 KITS AND REAGENTS

13.5.4 OTHER CONSUMABLES

14 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC CENTERS

14.4 CANCER RESEARCH CENTERS

14.5 ACADEMIC INSTITUTES

14.6 AMBULATORY SURGICAL CENTERS

14.7 OTHERS

15 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

15.4 OTHERS

16 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 INDIA

16.1.4 SOUTH KOREA

16.1.5 AUSTRALIA

16.1.6 TAIWAN

16.1.7 NEW ZEALAND

16.1.8 INDONESIA

16.1.9 THAILAND

16.1.10 PHILIPPINES

16.1.11 MALAYSIA

16.1.12 VIETNAM

16.1.13 SINGAPORE

16.1.14 REST OF ASIA PACIFIC

17 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 CANON MEDICAL SYSTEMS CORPORATION

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY PROFILE

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 KONINKLIJKE PHILIPS N.V.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY PROFILE

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 GENERAL ELECTRIC COMPANY

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY PROFILE

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 SIEMENS HEALTHCARE GMBH

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY PROFILE

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 GRAIL

19.5.1 COMPANY SNAPSHOT

19.5.2 PRODUCT PORTFOLIO

19.5.3 RECENT DEVELOPMENTS

19.6 AMBRY GENETICS

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BIOVENDOR R&D

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 BLUEPRINT GENETICS OY.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 CD GENOMICS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CENTOGENE N.V.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 CREATIVE DIAGNOSTICS

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 FUJIFILM CORPORATION

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 GENEDX, LLC

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 ILLUMINA, INC.

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 INVITAE CORPORATION

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 MYRIAD GENETICS, INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 QIAGEN

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS

TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER

TABLE 3 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 31 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 32 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 35 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 36 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA PACIFIC NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA PACIFIC FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA PACIFIC IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 49 ASIA PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 51 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 53 ASIA PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 ASIA PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 55 ASIA PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 ASIA PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 57 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 58 ASIA PACIFIC HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 ASIA PACIFIC DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 ASIA PACIFIC CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 ASIA PACIFIC ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 62 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 65 ASIA PACIFIC DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 ASIA PACIFIC RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 67 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 83 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 84 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 86 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 87 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 90 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 91 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 92 ASIA-PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 ASIA-PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 ASIA-PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 ASIA-PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 96 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 98 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 99 CHINA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 100 CHINA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 CHINA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 102 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 103 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 104 CHINA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 CHINA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 CHINA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 CHINA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 CHINA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 109 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 110 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 111 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 112 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 113 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 115 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 116 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 117 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 118 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 119 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 120 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 121 CHINA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 122 CHINA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 CHINA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 124 CHINA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 125 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 126 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 127 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 128 JAPAN IMAGING TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 JAPAN BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 JAPAN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 131 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 132 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 133 JAPAN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 134 JAPAN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 JAPAN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 136 JAPAN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 137 JAPAN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 139 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 140 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 141 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 142 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 144 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 145 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 146 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 147 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 148 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 149 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 150 JAPAN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 151 JAPAN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 152 JAPAN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 153 JAPAN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 154 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 155 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 157 INDIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 INDIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 INDIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 160 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 161 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 162 INDIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 163 INDIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 164 INDIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 165 INDIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 166 INDIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 168 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 169 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 170 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 171 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 172 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 173 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 174 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 175 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 176 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 177 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 178 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 179 INDIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 180 INDIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 INDIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 INDIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 183 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 184 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 185 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 SOUTH KOREA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 SOUTH KOREA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 188 SOUTH KOREA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 190 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 191 SOUTH KOREA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 SOUTH KOREA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 SOUTH KOREA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 194 SOUTH KOREA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 SOUTH KOREA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 196 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 198 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 199 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 200 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 202 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 203 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 205 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 206 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 207 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 208 SOUTH KOREA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 209 SOUTH KOREA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 210 SOUTH KOREA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 SOUTH KOREA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 212 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 215 AUSTRALIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 216 AUSTRALIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 217 AUSTRALIA BIOMAKER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA RENAL CELL CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 228 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 229 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 231 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 232 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 234 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 235 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 236 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 237 AUSTRALIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 238 AUSTRALIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 AUSTRALIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 AUSTRALIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 242 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 243 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 244 TAIWAN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 245 TAIWAN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 246 TAIWAN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 247 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 248 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 249 TAIWAN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 250 TAIWAN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 251 TAIWAN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 252 TAIWAN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 253 TAIWAN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 254 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 255 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 256 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 257 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 258 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 259 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 260 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 261 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 262 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 263 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 264 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 265 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 266 TAIWAN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 267 TAIWAN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 TAIWAN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 TAIWAN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 270 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 271 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 272 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 273 NEW ZEALAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 274 NEW ZEALAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 275 NEW ZEALAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 276 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 277 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 278 NEW ZEALAND RENAL CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 279 NEW ZEALAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 280 NEW ZEALAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 281 NEW ZEALAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 282 NEW ZEALAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 283 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 284 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 285 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 286 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 287 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 288 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 289 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 290 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 292 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 293 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 294 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 295 NEW ZEALAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 296 NEW ZEALAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 297 NEW ZEALAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 298 NEW ZEALAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 299 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 300 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 301 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 302 INDONESIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 303 INDONESIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 304 INDONESIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 305 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 306 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 307 INDONESIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 308 INDONESIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 309 INDONESIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 310 INDONESIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 311 INDONESIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 312 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 313 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 314 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 315 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 316 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 317 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 318 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 319 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 320 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 321 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 322 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 323 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 324 INDONESIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 325 INDONESIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 326 INDONESIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 327 INDONESIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 328 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 329 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 330 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 331 THAILAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 332 THAILAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 333 THAILAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 334 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 335 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 336 THAILAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 337 THAILAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 338 THAILAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 339 THAILAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 340 THAILAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 341 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 342 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 343 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 344 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 345 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 346 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 347 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 348 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 349 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 350 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 351 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 352 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 353 THAILAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 354 THAILAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 355 THAILAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 356 THAILAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 357 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 358 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 359 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 360 PHILIPPINES IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 361 PHILIPPINES BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 362 PHILIPPINES BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 363 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 364 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 365 PHILIPPINES RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 366 PHILIPPINES CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 367 PHILIPPINES NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 368 PHILIPPINES PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 369 PHILIPPINES CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 371 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 372 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 373 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 374 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 375 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 376 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 377 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 378 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 379 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 380 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 381 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 382 PHILIPPINES SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 383 PHILIPPINES DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 384 PHILIPPINES PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 385 PHILIPPINES RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 386 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 387 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 388 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 389 MALAYSIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 390 MALAYSIA BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 391 MALAYSIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 392 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 393 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 394 MALAYSIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 395 MALAYSIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 396 MALAYSIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 397 MALAYSIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 398 MALAYSIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 399 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 400 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 401 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 402 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 403 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 404 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 405 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 406 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 407 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 408 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 409 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 410 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 411 MALAYSIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 412 MALAYSIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 413 MALAYSIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 414 MALAYSIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 415 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 416 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 417 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 418 VIETNAM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 419 VIETNAM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 420 VIETNAM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 421 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 422 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 423 VIETNAM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 424 VIETNAM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 425 VIETNAM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 426 VIETNAM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 427 VIETNAM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 428 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 429 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 430 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 431 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 432 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 433 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 434 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 435 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 436 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 437 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 438 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 439 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 440 VIETNAM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 441 VIETNAM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 442 VIETNAM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 443 VIETNAM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 444 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 445 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 446 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 447 SINGAPORE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 448 SINGAPORE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 449 SINGAPORE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 450 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 451 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 452 SINGAPORE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 453 SINGAPORE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 454 SINGAPORE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 455 SINGAPORE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 456 SINGAPORE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 457 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 458 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 459 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 460 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 461 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 462 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 463 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 464 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 465 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 466 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 467 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 468 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 469 SINGAPORE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 470 SINGAPORE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 471 SINGAPORE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 472 SINGAPORE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 473 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 474 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 475 REST OF ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Lista de Figura

FIGURE 1 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET

FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020)

FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020)

FIGURE 16 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022

FIGURE 17 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 18 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)

FIGURE 19 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022

FIGURE 21 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 22 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030)

FIGURE 23 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022

FIGURE 25 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION)

FIGURE 26 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030)

FIGURE 27 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022

FIGURE 29 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 30 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030)

FIGURE 31 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE

FIGURE 32 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022

FIGURE 33 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 34 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 35 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE

FIGURE 36 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022

FIGURE 37 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 38 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030)

FIGURE 39 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 40 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022

FIGURE 41 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)

FIGURE 42 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)

FIGURE 43 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022

FIGURE 45 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 46 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 47 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 49 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 50 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 51 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 52 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 53 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

What is the forecasted growth of this market?

The Asia-Pacific Kidney Cancer Diagnostics Market will grow a 6.9% CAGR from 2023 to 2030.

What will be the market value in the future?

Asia-Pacific Kidney Cancer Diagnostics Market will expand $3,240.00 million by 2030.

Which market segments are covered in this report?

Asia-Pacific Kidney Cancer Diagnostics Market is fragmented by test type, cancer stage, tumor type, product, application, technology, end user & distribution mode.

Which countries data are covered in the report?

The countries covered in this market report are China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan, and the rest of Asia-Pacific.

Which region dominates the market ?

China dominates the Asia-Pacific region due to rising awareness of regular health checkups.

Mercado de diagnóstico de cancro renal Ásia-Pacífico – Tendências e previsões do setor para 2030

Mercado de diagnóstico de cancro renal Ásia-Pacífico – Tendências e previsões do setor para 2030

Asia Pacific Kidney Cancer Diagnostics Market

CAGR : 6.90 %

Análise e dimensão do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Dinâmica do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Âmbito do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Análise/perspetivas regionais do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Análise do panorama competitivo e da quota de mercado de diagnóstico de cancro renal da Ásia-Pacífico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Mercado de diagnóstico de cancro renal Ásia-Pacífico – Tendências e previsões do setor para 2030

Mercado de diagnóstico de cancro renal Ásia-Pacífico – Tendências e previsões do setor para 2030

Asia Pacific Kidney Cancer Diagnostics Market

CAGR : 6.90 %

Análise e dimensão do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Dinâmica do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Âmbito do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Análise/perspetivas regionais do mercado de diagnóstico de cancro renal da Ásia-Pacífico

Análise do panorama competitivo e da quota de mercado de diagnóstico de cancro renal da Ásia-Pacífico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas